| Design of a Small-Molecule Entry Inhibitor with Activity against Primary Measles Virus Strains | |||||||||||||
Abstract | |||||||||||||
| The incidence of measles virus (MV) infection has been significantly reduced in many nations through extensive vaccination; however, the virus still causes significant morbidity and mortality in developing countries. Measles outbreaks also occur in some developed countries that have failed to maintain high vaccine coverage rates. While vaccination is essential in preventing the spread of measles, case management would greatly benefit from the use of therapeutic agents to lower morbidity. Thus, the development of new therapeutic strategies is desirable. We previously reported the generation of a panel of small-molecule MV entry inhibitors. Here we show that our initial lead compound, although providing proof of concept for our approach, has a short half-life ( | |||||||||||||
Details der Publikation | |||||||||||||
| |||||||||||||